Clinical Trials Logo
  1. Home
  2. Central Retinal Vein Occlusion
  3. NCT01178697
  4. Details
NCT01178697 Clinical Trial

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion Clinical Trial

Official title:
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01178697
Other study ID # 8886
Secondary ID
Status Recruiting
Phase Phase 2
First received August 2, 2010
Last updated August 9, 2010
Start date January 2010
Est. completion date December 2010

Study information
Verified date January 2010
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Recruitment information / eligibility
Status Recruiting
Enrollment 0
Est. completion date December 2010
Est. primary completion date September 2010
Accepts healthy volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Recent onset (less than 3 months) central retinal vein occlusion

Exclusion Criteria:

- Any previous intervention

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Bevasizumab
Intravitreal, 1.25 mg, 3 times, one month apart.
• Triamcinolone Acetonide
Intravitreal, 2 mg, 2 times, two months apart.

Locations
Country Name City State
Iran, Islamic Republic of Imam Hossein medical center Tehran

Sponsors (2)
Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences Ophthalmic Research Center

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Visual acuity 6 months No
Secondary central macular thickness 6 months No
See also
  Status Clinical Trial Phase
Completed NCT01969708 - Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Completed NCT03981549 - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Phase 1/Phase 2
Completed NCT02274259 - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Phase 4
Completed NCT01360385 - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab N/A
Not yet recruiting NCT00383773 - Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion N/A
Completed NCT00952614 - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion N/A
Recruiting NCT04601701 - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Withdrawn NCT03417401 - Surgical Stabilizer Assisted RVC With rtPA for CRVO Phase 1
Completed NCT01976312 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Phase 3
Completed NCT01724554 - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Phase 1/Phase 2
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Active, not recruiting NCT01011374 - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion Phase 1
Completed NCT03223714 - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Phase 3
Recruiting NCT01827722 - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Phase 4
Completed NCT00906685 - Bevacizumab for Central Retinal Vein Occlusion Study Phase 3
Active, not recruiting NCT04793100 - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections N/A
Recruiting NCT02405741 - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Phase 2